<DOC>
	<DOCNO>NCT02153073</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy long-term use granular capsule formulation omega-3 fatty acid ethyl ester ( Lotriga Granular Capsules ) patient hyperlipidemia daily medical practice</brief_summary>
	<brief_title>Evaluation Safety Efficacy Long-term Use Lotriga</brief_title>
	<detailed_description>This special drug use surveillance long-term use granular capsule formulation omega-3 fatty acid ethyl ester ( Lotriga Granular Capsules ) design investigate frequency adverse event patient hyperlipidemia The usual adult dosage 2 g omega-3 fatty acid ethyl ester administer orally daily meal . However , dosage increase twice daily ( dose 2 g ) depend patient 's triglyceride level .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Patients hyperlipidemia ( 1 ) Patients hemorrhage ( e.g. , hemophilia , capillary fragility , gastrointestinal ulcer , urinary tract hemorrhage , hemoptysis , vitreous hemorrhage ) ( 2 ) Patients history hypersensitivity ingredient Lotriga Granular Capsules</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>